NIH clinical trial funding is about to look different. On November 10, 2026, NIH announced on its Extramural Nexus blog that its Institutes, Centers, and Offices (ICOs) are building a suite of broad clinical trial funding opportunities organized by the type of trial, not by disease or scientific topic. Five trial types will map to three familiar activity codes: R34, R61/R33, and UG3/UH3.
For investigators, the goal is a simpler search. For pre-award offices, the change touches how proposals are routed, how phased budgets are built, and when IRB, site, and subaward work has to start. It is also not finished: NIH says the opportunities are forecasts under review and will roll out in phases.
This post explains what NIH has actually said, what the forecasts show so far, and what sponsored programs and clinical research offices can do now.
In This Article
- What NIH Announced on November 10
- The New NIH Clinical Trial Funding Suite at a Glance
- What Changes for Proposal Routing and Pre-Award Review
- A Pre-Award Checklist for the New Clinical Trial NOFOs
- How Fibi Helps Pre-Award and IRB Offices
- Key Takeaways
What NIH Announced on November 10
From topic-specific announcements to trial types
Until now, many ICOs wrote their own clinical trial notices of funding opportunity (NOFOs) or joined co-funded announcements tailored to their science. NIH acknowledges that this produced “a complex landscape for investigators, who often encountered different application instructions, review criteria, and ICO-specific processes and requirements.”
The new approach has ICOs jointly developing broad NOFOs around the kind of trial being proposed, spanning “feasibility testing through implementation research.” NIH says the suite will:
- make it easier to find the right NOFO;
- provide consistent application instructions for similar trial types;
- improve the methodological rigor of applications;
- support coordination and co-funding across ICOs; and
- improve NIH’s own planning and tracking of clinical trials.
What is not changing
Three points in the announcement matter for anyone updating internal guidance:
- Parent announcements stay. The suite will “complement the currently existing NIH Parent Announcements,” not replace them.
- Targeted NOFOs continue. Applicants “may also still see targeted clinical trial funding opportunities from individual ICOs based on specific programmatic needs.”
- Science still drives funding. NIH says scientific priorities “remain central,” communicated through ICO profile pages, strategic plans, and Highlighted Topics.
NIH also notes “some intentional overlap” between the trial types so that no study falls through the gaps.
The New NIH Clinical Trial Funding Suite at a Glance
The table below combines NIH’s description of each trial type with the matching Grants.gov forecasts. NIH’s post does not list forecast numbers in its text; the mapping of numbers to trial types comes from an NIA-affiliated Clin-STAR update, and we confirmed each forecast on Simpler.Grants.gov. Every date below is an estimate, and NIH says forecasts are “informational only.”
| Trial type | Activity code | What it supports (per NIH) | Forecast (as of Nov 13, 2026) |
|---|---|---|---|
| Feasibility Trials | R34 | Feasibility trials that prepare for later Phase II-IV or Stage II-V, efficacy, effectiveness, pragmatic, or implementation trials | PAR-28-011: est. post Nov 24, 2026; est. due Feb 16, 2027 |
| Early to Definitive Trials | R61/R33 | Early-phase trials (first in human, safety, dosing, Phase I) through early definitive trials (Phase II, efficacy) | PAR-28-074: est. post May 31, 2027; est. due Jul 31, 2027; max 7 years |
| Multi-Site Trials | UG3/UH3 | Multi-site efficacy, effectiveness, or hybrid trials, plus large decentralized or virtual mHealth trials | PAR-27-125: est. post Nov 16, 2026; est. due Feb 16, 2027; UG3 up to 2 years, UH3 up to 5 |
| Pragmatic & Implementation Trials | UG3/UH3 | Large pragmatic trials in real-world health care or public health settings (e.g., Phase III-IV) | PAR-28-010: est. post Nov 24, 2026; est. due Feb 23, 2027 |
| Network Trials | UG3/UH3 | Any type of trial that uses the infrastructure of an NIH-funded clinical trial network | PAR-27-007: forecast dates (Oct 10 post, Nov 10 due) have passed; not yet published |
Two cautions. First, the network forecast still shows October and November 2026 dates, but no NOFO had appeared in the NIH Guide as of November 13, so treat those dates as out of date. Second, the R61/R33 forecast points to mid-2027, so the suite will arrive over many months, not all at once.
What Changes for Proposal Routing and Pre-Award Review
Routing starts with trial type, not institute
Today, a pre-award specialist often starts by asking which institute funds the science, then looks for that institute’s clinical trial NOFO. Under the suite, the first question becomes: what kind of trial is this? A feasibility study points to R34, an early-phase trial to R61/R33, and a multi-site, pragmatic, or network trial to one of three UG3/UH3 options. The institute question still matters for fit, assignment, and program contact, but it moves to second place.
Remember that NIH requires clinical trials to be submitted to a NOFO designated for clinical trials. Check NIH’s clinical trial requirements page and the clinical trial definition before routing, because a study that is not a clinical trial will not fit this suite.
Phased, milestone-driven awards need more planning
Four of the five trial types use bi-phasic awards. The forecasts describe R61 as a planning phase and R33 as the trial phase, and the multi-site UG3/UH3 forecast says a UG3 project that meets its milestones “will be administratively considered” for transition to the UH3. For pre-award offices, that means separate budgets and justifications by phase, clear milestones that reviewers and program staff can check, and a realistic start-up timeline.
Cooperative agreements and multi-site logistics
Three of the five types are UG3/UH3 cooperative agreements, which involve substantial NIH program involvement. Multi-site and network trials usually also bring subaward and site budgets, data coordination, single IRB arrangements for multi-site human subjects research, and network approvals. Those items take weeks, so they cannot wait for the final internal deadline.
A new application form may follow
Separately, NIH is revising a proposed Clinical Trial Specific Application Form (NOT-OD-26-058) that would combine clinical trial information into one structured form with page limits. In September, NIH said it is modifying the form after public comments and will fold it into next-generation application forms. No implementation date has been announced, but it is worth watching alongside the NOFO suite.
A Pre-Award Checklist for the New Clinical Trial NOFOs
1. Track the forecasts now
Save the five forecasts and set alerts on Grants.gov or Simpler.Grants.gov. Note the estimated due dates (several fall in February 2027) and treat them as tentative until each NOFO publishes.
2. Add a trial-type question to intake
Ask PIs early whether the study is feasibility, early-phase, multi-site, pragmatic or implementation, or network-based. Pair that with the four NIH clinical trial questions so routing decisions are documented.
3. Prepare phased budget templates
Build R61/R33 and UG3/UH3 templates that split costs by phase and show start-up versus enrollment periods. Our FY2027 research budget planning guide covers the wider funding pressures that shape these budgets.
4. Start IRB and site planning before submission
For multi-site and network trials, confirm the single IRB plan, reliance agreements, and site letters early. Safety monitoring expectations are changing too; see our post on NIH’s draft data and safety monitoring policy.
5. Revisit active ICO-specific NOFOs
Some institute-specific clinical trial NOFOs remain open, with expiration dates as late as 2029. Do not assume a PI’s usual announcement is gone, but check whether a suite NOFO is a better fit.
6. Read every final NOFO closely
When each NOFO publishes, compare it to its forecast: participating ICOs, due dates, page limits, milestone rules, and any special review criteria. Update your internal guidance once, then share it with departments.
How Fibi Helps Pre-Award and IRB Offices
A trial-type framework works best when your proposal data is structured the same way. Fibi Grant Management supports proposal development through award management, and Fibi IRB supports human subjects review.
- Proposal intake: capture trial type, activity code, and target NOFO on each proposal record so routing is consistent.
- Phased budgets: keep planning-phase and implementation-phase budgets together for R61/R33 and UG3/UH3 applications.
- Linked IRB records: connect proposals to IRB protocols and reliance status, so single IRB questions surface before submission.
- Reporting: see how many clinical trial proposals are in progress by trial type and sponsor.
Sponsor terms are shifting on the post-award side as well; see our Uniform Guidance agency tracker for the latest.
Key Takeaways
- NIH announced on November 10, 2026 that it is building broad NIH clinical trial funding opportunities organized by trial type, using R34, R61/R33, and UG3/UH3.
- The five types are feasibility, early to definitive, multi-site, pragmatic and implementation, and network trials.
- The NOFOs are forecasts under review; estimated due dates start in February 2027, and the R61/R33 NOFO is not expected until mid-2027.
- Parent announcements and targeted ICO NOFOs will continue alongside the suite.
- Pre-award offices should add trial type to intake, build phased budget templates, and start IRB and site planning earlier.
This post summarizes public information as of November 13, 2026. Forecast dates are estimates and may change. Always confirm requirements in the published NOFO and with NIH program staff.